Nizatidine and clarithromycin: an effective combination therapy in the treatment of helicobacter pylori associated peptic ulcer

Helicobacter pylori is now accepted as the cause of chronic active type B gastritis and also having a critical role in duodenal ulcer. Most anti-Helicobacter pylori regimens available have drawbacks of adverse effects, prolonged therapy and resistance. The introduction of eradication regimens based on acid suppression in combination with antibiotics are yielding promising results. Combination of Nizatidine 300 mg BID with Clarithromycin 500 mg TID were tried in endoscopically proven Helicobacter Pylori positive patients for 15 days. Endoscopy after 30 days showed healing of 95.2% of ulcers and eradication of Helicobacter pylori infection in the same percentage. It is concluded that this is an effective combination